Cargando…

Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages — United States, January 2023

Detalles Bibliográficos
Autores principales:	Patel, Pragna, Twentyman, Evelyn, Koumans, Emily, Rosenblum, Hannah, Griffin-Blake, Shannon, Jackson, Brendan, Vagi, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2023
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927066/ https://www.ncbi.nlm.nih.gov/pubmed/36730033 http://dx.doi.org/10.15585/mmwr.mm7205e3

Ejemplares similares

Continued Complexity of Mutations in Omicron Sublineages
por: Spratt, Austin N., et al.
Publicado: (2022)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
por: Andrade-Molina, D.A., et al.
Publicado: (2023)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

In the Literature: January 2023
por: Martín-Arana, J., et al.
Publicado: (2023)

January 2023 obituaries
Publicado: (2023)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages
por: Wang, Yuliang, et al.
Publicado: (2023)

Rapid emergence of omicron sublineages expressing spike protein R346T
por: Groenheit, Ramona, et al.
Publicado: (2022)

Inaugural Editorial, January 2023
por: Gaut, Brandon S, et al.
Publicado: (2023)

Editors’ Pick in January 2023
por: Yang, Hee-Jin, et al.
Publicado: (2023)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
por: Park, Young-Jun, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
por: Haars, Jonathan, et al.
Publicado: (2023)

The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant — Jiangsu Province, China, December 2022 to January 2023
por: Zhang, Chuanmeng, et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart
por: Girardi, Viviane, et al.
Publicado: (2023)

PUBLIC MEETING - January 2023 - Recording
por: Staff Association
Publicado: (2023)

Salary Scale 1 January 2023
por: Stappers, Sara
Publicado: (2023)

Actuarial dashboard as at 1 January 2023
Publicado: (2023)

JHEP at a glance (January 2023)
Publicado: (2023)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
por: Wang, Yizhen, et al.
Publicado: (2023)

2023 January issue Journal of Orthopaedic Translation
por: Xiao, Guozhi
Publicado: (2023)

Human vaccines & immunotherapeutics: News January 2023
por: Ellis, Ronald, et al.
Publicado: (2023)

The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023
por: Cai, Chunsheng, et al.
Publicado: (2023)

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages — United States, January 2022–May 2023
por: Ma, Kevin C., et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q163jo34lpe08ot3pvrc9fpm8h